Category: Politics

Chemotherapy-Induced Diarrhea Pipeline Expected to Witness the Entry of Novel Therapies in the Coming Decade | DelveInsight

Post author By sthakur
Post date September 28, 2021
No Comments on Chemotherapy-Induced Diarrhea Pipeline Expected to Witness the Entry of Novel Therapies in the Coming Decade | DelveInsight

DelveInsight’s ‘Chemotherapy-induced Diarrhea Pipeline Insights‘ report offers comprehensive coverage of the emerging Chemotherapy-induced Diarrhea therapeutics space in different stages of development from pre-clinical till a late-end stage, along with dormant, inactive and abandoned drugs agents.

The Chemotherapy-induced Diarrhea Pipeline report provides a comprehensive view of the clinical trials, partnerships and collaborations, recent happenings in the space and growth prospects across the Chemotherapy-induced Diarrhea domain.

Some of the key takeaways from the Chemotherapy-induced Diarrhea Pipeline report:

The Chemotherapy-induced Diarrhea Pipeline report offers a rich analysis of 5+ key players and 5+ key therapies.
Chemotherapy-induced Diarrhea pipeline comprises emerging therapies in different stages of the clinical phase such as FW-420, Mytesi, OQL051, DP 1038 and others.
Some of the key companies working to strengthen the Chemotherapy-induced Diarrhea Pipeline are AzuRx BioPharma, Napo Pharmaceuticals, OnQuality Pharmaceuticals, Dauntless Pharmaceuticals, among others.

Request for Sample report to discover more about the therapies set to grab maximum patient pool @ https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-pipeline-insights

Chemotherapy-induced Diarrhea (CID) is a side-effect of frequently used chemotherapy agents and can lead to delays in treatment and poor quality of life. It is a common problem, especially in patients with advanced cancer and is most often described with fluoropyrimidines (particularly fluorouracil [FU] and capecitabine) and irinotecan.

For more information on emerging drugs, visit: https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-pipeline-insights

Chemotherapy-induced Diarrhea Pipeline Drugs Immunostimulants

Drug	Company	Phase	MoA	RoA
FW-420	AzuRx BioPharma	Unknown	MTOR protein inhibitors	Oral/rectal
Mytesi	Napo Pharmaceuticals	Phase III	Chloride channel antagonists	Oral
OQL051	OnQuality Pharmaceuticals	Discovery	NA	NA
DP 1038	Dauntless Pharmaceuticals	Phase II	Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists	Intranasal

Request for Sample to know more @ https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-pipeline-insights

Chemotherapy-induced Diarrhea Therapeutic Assessment

The Chemotherapy-induced Diarrhea Pipeline report lays down complete insights into active Chemotherapy-induced Diarrhea pipeline therapies segmented into Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

Scope of the Report
Coverage: Global
Key Players: AzuRx BioPharma, Napo Pharmaceuticals, Dauntless Pharmaceuticals, OnQuality Pharmaceuticals and others.
Key Chemotherapy-induced Diarrhea Pipeline Therapies: FW-420, Mytesi, DP 1038, OQL051 and others.

Reach out @ https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-pipeline-insights

Table of Contents

1	Report Introduction
2	Chemotherapy-induced Diarrhea Disease Overview
3	Chemotherapy-induced Diarrhea Pipeline Outlook
4	Comparative Analysis
5	Chemotherapy-induced Diarrhea Therapeutic Products in Clinical Stage
6	Chemotherapy-induced Diarrhea Therapeutic Products in Non-clinical Stage
7	Chemotherapy-induced Diarrhea Therapeutics Pipeline Analysis
8	Inactive Chemotherapy-induced Diarrhea Pipeline Products
9	Appendix
10	Report Methodology
11	Consulting Services
12	Disclaimer
13	About DelveInsight

Visit to know more of what’s covered @ https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-pipeline-insights

Some of Newly Launched Report:

Other Links:

· T-Cell-Prolymphocytic Leukemia Market

· Cipn Market

· Barett Esophagus Market

· Post Traumatic Stress Disorder Market

· Oral Mucositis Market

About Delveinsight:

DelveInsight Business Research is a leading Market Research, and Healthcare Consulting focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: [email protected]

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com/

Tags Chemotherapy-Induced Diarrhea, Chemotherapy-Induced Diarrhea clinical trials, Chemotherapy-Induced Diarrhea companies, Chemotherapy-Induced Diarrhea Pipeline

Electric vehicles Energy Environment Finances Military NASA Politics Satellites Science Space Technology

Obesity Pipeline: Industry Analysis, Key Pharma Companies, Clinical Trials and Drug Pipeline by DelveInsight

Post author By sthakur
Post date September 28, 2021
No Comments on Obesity Pipeline: Industry Analysis, Key Pharma Companies, Clinical Trials and Drug Pipeline by DelveInsight

DelveInsight’s Obesity Pipeline Insight report offers exhaustive global coverage of available pipeline therapies in different phases of clinical development, key companies working to advance the pipeline space, and future growth potential of the Obesity pipeline domain.

Some of the significant pointers taken from the Obesity Pipeline report:

DelveInsight’s analysis presents Obesity Pipeline with 80+ active players in the domain investigating 80+ pipeline therapies.
Major companies such as ERX Pharmaceuticals, Amgen, Allysta Pharmaceuticals, Empros Pharma, Innovent Biologics, Pfizer, Boehringer Ingelheim, MedImmune LLC, Scohia Pharma, Eli Lilly and Company, and others are developing potential drug candidates to improve the Obesity treatment scenario.
Key Obesity pipeline therapies such as ERX1000, AMG 171, ALY688-SR, EMP16-02, IBI362, PF-06882961, BI 456906, SCO-094, MEDI0382, Tirzepatide, and others are under investigation in different phases of clinical trials for the treatment of Obesity.
In July 2021, AstraZeneca collaborated with Regeneron to foster research, develop and commercialize small molecule compounds directed against the GPR75 target with the potential to treat Obesity and related co-morbidities.
In June 2021, Innovent Biologics announced that the first subject had been successfully dosed in Phase II clinical trial (NCT04904913) of IBI362, a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist in China.
In April 2021, Boehringer Ingelheim and Zealand Pharma announced the initiation of two Phase II trials of the GLP-1/glucagon dual agonist BI 456906 for adults who are overweight or obese and for adults with non-alcoholic steatohepatitis (NASH).

Request for Sample to know which pharma company is expected to be at the forefront in the coming years @ https://www.delveinsight.com/sample-request/obesity-pipeline-insight

The Obesity pipeline report lays down detailed profiles of the Obesity pipeline assets as well as the inactive and dormant Obesity drug assets, comparative analysis of clinical and non-clinical stage Obesity products, rich assessment of driving and restraining factors, along with the opportunities and risks in the Obesity pipeline landscape.

Obesity Overview

Obesity is a complex disorder that involves the accumulation of excessive amounts of fat in the body. It is a medical problem that is associated with the heightened risks of other health conditions such as diabetes, heart disease, cancers, high blood pressure, and other cardiovascular diseases. At present, Obesity has become a global concern causing the death of more than 4 million people each year.

Discover more about the disease, therapies, and Obesity pipeline activity @ https://www.delveinsight.com/sample-request/obesity-pipeline-insight

Obesity Pipeline Drugs

Drug	Company	Phase	MoA	RoA
SCO-094	Scohia Pharma	Phase I	Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide 1 receptor agonists	Oral
ERX1000	ERX Pharmaceuticals	Phase I	leptin sensitizer	Oral
AMG 171	Amgen	Phase I	Undefined mechanism	NA
ALY688-SR	Allysta Pharmaceuticals	Phase I	Adiponectin receptor agonists	Subcutaneous
EMP16-02	Empros Pharma	Phase II	Alpha-glucosidase inhibitors; Amylase inhibitors; Lipase inhibitors	Oral
IBI362	Innovent Biologics	Phase II	Glucagon-like peptide 1 receptor agonists; Glucagon receptor agonists	Subcutaneous
BI 456906	Boehringer Ingelheim,	Phase II	Glucagon-like peptide 1 receptor agonists; Glucagon receptor agonists	Subcutaneous
MEDI0382	MedImmune LLC,	Phase II	Glucagon receptor agonists; Glucagon-like peptide 1 stimulants	Subcutaneous
Tirzepatide	Eli Lilly and Company	Phase III	Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide 1 receptor agonists	Subcutaneous
PF-06882961	Pfizer	Phase II	Glucagon-like peptide 1 receptor agonists	Oral

Request for Sample to know more @ https://www.delveinsight.com/sample-request/obesity-pipeline-insight

Obesity Therapeutics Assessment

The Obesity Pipeline report proffers a comprehensive picture of the novel Obesity pipeline therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

By Product Type

Mono
Combination
Mono/Combination

By Stage

Discovery
Pre-clinical
Phase I
Phase II
Phase III
Pre-registration

By Route of Administration

Subcutaneous
Oral

By Molecule Type

Small molecules
Peptides
Lactones

By Mechanism of Action

Gastric inhibitory polypeptide receptor agonists
Glucagon-like peptide 1 receptor agonists
Adiponectin receptor agonists
Alpha-glucosidase inhibitors
Amylase inhibitors
Lipase inhibitors

By Targets

Gastric inhibitory polypeptide receptor
Glucagon-like peptide 1 receptor
Adiponectin receptor
Alpha-glucosidase
Amylase
Lipase

Scope of the Obesity Pipeline Report

Coverage: Global
Major Players: ERX Pharmaceuticals, Amgen, Allysta Pharmaceuticals, Empros Pharma, Innovent Biologics, Pfizer, Boehringer Ingelheim, MedImmune LLC, Scohia Pharma, Eli Lilly and Company
Key Obesity Pipeline Therapies: ERX1000, AMG 171, ALY688-SR, EMP16-02, IBI362, PF-06882961, BI 456906, SCO-094, MEDI0382, Tirzepatide

For rich insights into emerging therapies and assessment, visit @ https://www.delveinsight.com/sample-request/obesity-pipeline-insight

Table of Contents

1	Introduction
2	Executive Summary
3	Obesity: Overview
4	Pipeline Therapeutics
5	Late Stage Products (Phase III)
6	Mid Stage Products (Phase II)
7	Mid Stage Products (Phase II)
8	Early Stage Products (Phase I/II)
9	Early Stage Products (Phase I)
10	Preclinical and Discovery Stage Products
11	Inactive Products
12	Therapeutic Assessment
13	Inactive Products
14	Obesity Key Companies
15	Obesity Key Products
16	Obesity- Unmet Needs
17	Obesity- Market Drivers and Barriers
18	Appendix
19	About DelveInsight

Some of Newly Launched Report:

About Delveinsight:

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: [email protected]

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com/

Tags Obesity, Obesity clinical trials, Obesity companies, Obesity Pipeline

Electric vehicles Energy Environment Finances Military NASA Politics Satellites Science Space Technology

Acute Lung Injury Market: Industry Analysis, Drugs, Key Companies by DelveInsight | Altor BioScience, Apeiron Biologics, Theravance Biopharma, Viela Bio, ReAlta Life Sciences, Cantex Pharmaceuticals, Asklepion Pharmaceuticals and Others

Acute Lung Injury is a life-threatening condition caused by severe acute hypoxemic respiratory failure. It is a key source of mortality and morbidity in critically ill patients without any evidence of hydrostatic pulmonary edema. Symptoms observed in acute lung injury include severe shortness of breath, low blood pressure, confusion, and extreme tiredness. This type of injury has a substantial impact on public health, with a high incidence across the world and it requires administration of a fast and goal-oriented therapy to suppress further lung damage.

DelveInsight’s “Acute Lung Injury Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Acute Lung Injury, historical and forecasted epidemiology as well as the Acute Lung Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some Facts of Acute Lung Injury Market Report:

The rising prevalence of acute lung injuries is expected to boost market growth over the forecast period.
For instance, according to the National Heart, Lung, and Blood Institute, 79 people per 100,000 population per year developed acute lung injury (ALI), and 59 of these met the criteria for the more severe form of acute respiratory distress syndrome. The death rate of acute lung injury patients was around 5 %.
Using the US census and assuming the same frequency throughout the country, 190,600 people per year develop ALI, and 74,500 dies off, or with, the disease in the US. Thus, the rising prevalence of acute lung injuries is driving the market.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/acute-lung-injury-market

Some of Acute Lung Injury Companies are:

Altor BioScience
Apeiron Biologics
Theravance Biopharma
Viela Bio
ReAlta Life Sciences
Cantex Pharmaceuticals
Asklepion Pharmaceuticals
Stemedica Cell Technologies
Forschung und Entwicklung
FirstString Research
Histocell S.L.
GlaxoSmithKline
S-Evans Biosciences
CompleGen
Commence Bio
Windtree Therapeutics
And Many Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/acute-lung-injury-market

Scope of Acute Lung Injury Market:

The report covers the descriptive overview of Acute Lung Injury, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Acute Lung Injury epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Acute Lung Injury are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Acute Lung Injury market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acute Lung Injury market

Some of Acute Lung Injury Therapies are:

APN01
TD-0903
VIB7734
RLS 0071
Dociparstat sodium
L-citrulline
And Many Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/acute-lung-injury-market

Key Acute Lung Injury Market Questions:

What was the Acute Lung Injury market share (%) distribution in 2017 and how it would look like in 2030?
What would be the Acute Lung Injury total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Acute Lung Injury market size during the forecast period (2017-2030)?
At what CAGR, the Acute Lung Injury market is expected to grow in 7MM during the forecast period (2017-2030)?
What would be the Acute Lung Injury market outlook across the 7MM during the forecast period (2017-2030)?
What would be the Acute Lung Injury market growth till 2030, and what will be the resultant market Size in the year 2030?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Request for Free Sample Report: https://www.delveinsight.com/sample-request/acute-lung-injury-market

Table of Contents:

Key Insights
Executive Summary of Acute Lung Injury
Competitive Intelligence Analysis for Acute Lung Injury
Acute Lung Injury: Market Overview at a Glance
Acute Lung Injury: Disease Background and Overview
Patient Journey
Acute Lung Injury Epidemiology and Patient Population
Treatment Algorithm, Current Treatment, and Medical Practices
Unmet Needs
Key Endpoints of Acute Lung Injury Treatment
Marketed Products

List to be continued in report

Emerging Therapies

List to be continued in report

Acute Lung Injury: Seven Major Market Analysis
Attribute analysis
7MM: Market Outlook
Access and Reimbursement Overview of Acute Lung Injury
KOL Views
Market Drivers
Market Barriers
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

Discuss the evolving trends of market landscape @ Acute Lung Injury Market Forecast

Get in touch with our Business executive for Rich and Deep Market Assessment and Consulting Solutions

Other Links:

· T-Cell-Prolymphocytic Leukemia Market

· Cipn Market

· Barett Esophagus Market

· Post Traumatic Stress Disorder Market

· Oral Mucositis Market

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Contact us

Ankit Nigam

[email protected]

+91-9650213330

https://www.delveinsight.com/

Connect With Us at:

LinkedIn | Facebook | Twitter

Request for Free Sample Report: https://www.delveinsight.com/sample-request/acute-lung-injury-market

Familial Primary Pulmonary Hypertension Market

Tags Acute Lung Injury, Acute Lung Injury Companies, Acute Lung Injury disease, Acute Lung Injury drugs, Acute Lung Injury epidemiology, Acute Lung Injury market, Acute Lung Injury market forecast, Acute Lung Injury market research, Acute Lung Injury market share, Acute Lung Injury market size, Acute Lung Injury market trends, Acute Lung Injury pipeline, Acute Lung Injury sales forecasting, Acute Lung Injury treatment algorithm

Electric vehicles Energy Environment Finances Military NASA Politics Satellites Science Space Technology

Contraceptive Devices Market: Industry Analysis, Devices, Companies and Competitive Landscape by DelveInsight

Post author By sthakur
Post date September 28, 2021
No Comments on Contraceptive Devices Market: Industry Analysis, Devices, Companies and Competitive Landscape by DelveInsight

Contraceptive devices are used for birth control by preventing unwanted pregnancies. Devices such as condoms, vaginal rings, IUDs are among a few of the contraceptive devices available in the market. Apart from preventing unintended pregnancies some of the contraceptive devices are also used as a prevention of sexually transmitted diseases.

DelveInsight’s ‘Contraceptive Devices Market Insights, Competitive Landscape and Market Forecast – 2026’ report delivers an in-depth understanding of Contraceptive Devices and the historical and forecasted Contraceptive Devices market trends in the US, EU5 (Germany, France, Spain, Italy, and United Kingdom) and Japan.

Some key facts of the Contraceptive Devices Market:

Global Contraceptive Devices Market is expected to grow at a CAGR of 6.71% during the forecast period from 2021 to 2026.
The demand for Contraceptive Devices is primarily attributed to the increasing number of unwanted pregnancies and the rising awareness regarding the complications associated with sexually transmitted diseases (STDs). In addition, rising education regarding female health and government policies to curb the burgeoning population growth are also the driving factors for contraceptive device market growth.
According to a study published by WHO 2019, globally, 74 million women living in low and middle-income countries have unintended pregnancies annually.
As per the study published in LANCET 2020, in 2015–19, there were 121.0 million unintended pregnancies annually with an 80% uncertainty interval, corresponding to a global rate of 64 unintended pregnancies per 1000 women aged 15–49 years.

Request for Sample Report: https://www.delveinsight.com/sample-request/contraceptive-devices-market

Some of the Contraceptive Devices Companies are:

Bayer Healthcare
Cooper Surgical Inc.
Teva Pharmaceutical Industries Ltd
Reckitt Benckiser
FemCap Inc.
The Female Health Company
Meril Life Sciences
Pregna International
And others

Contraceptive Devices Market Drivers

The major factors driving the demand for Contraceptive Devices are the rising concern of overpopulation in many countries, the increasing number of unintended pregnancies, and complications associated with STDs. Also, rising government initiatives for raising awareness regarding contraception are a driving factor in low-income and developing countries.

Request for Sample Report: https://www.delveinsight.com/sample-request/contraceptive-devices-market

Scope of the Contraceptive Devices Market Report

The report covers the descriptive overview of Contraceptive Devices, explaining its applications, advantages, and limitations, etc.
Additionally, an all-inclusive account of the currently available Contraceptive Devices is provided, which will have an impact on the future market of Contraceptive Devices
A detailed review of Contraceptive Devices market; historical and forecasted market size is included in the report, covering devices outreach in the 7MM.
The report provides an edge while developing business strategies, by understanding trends shaping and driving the Contraceptive Devices market.

Request for Sample Report: https://www.delveinsight.com/sample-request/contraceptive-devices-market

Table of Contents:

Key Insights
Executive Summary of Contraceptive Devices
Contraceptive Devices: Background and Overview
Contraceptive Devices: Regulatory Scenario
Contraceptive Devices: Reimbursement Scenario
Company Profiles

6.1. Bayer Healthcare

6.2. Cooper Surgical Inc

Products detail in the report…

Contraceptive Devices: Competitive Analysis
KOL Views
Contraceptive Devices: Market Analysis in 7MM
Country-Wise Market size of Contraceptive Devices in 7MM (2018–2026)
Market Dynamic
PEST Analysis
Conclusion and Future Perspective
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

Related Reports:

· T-Cell-Prolymphocytic Leukemia Market

· Cipn Market

· Barett Esophagus Market

· Post Traumatic Stress Disorder Market

· Oral Mucositis Market

About Delveinsight:

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: [email protected]

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com/

Familial Primary Pulmonary Hypertension Market

Tags Contraceptive Devices, Contraceptive Devices Companies, Contraceptive Devices Industry, Contraceptive Devices Market, Contraceptive Devices Market Share, Contraceptive Devices Market Size, Contraceptive Devices Mechanism, Contraceptive Devices Medical devices

Electric vehicles Energy Environment Finances Military NASA Politics Satellites Science Space Technology

Oral Mucositis Market: Industry Analysis, Epidemiology, Treatment, Drugs and Companies by DelveInsight

Post author By sthakur
Post date September 28, 2021
No Comments on Oral Mucositis Market: Industry Analysis, Epidemiology, Treatment, Drugs and Companies by DelveInsight

DelveInsight’s “Oral Mucositis Market Insights, Epidemiology and Market Forecast – 2030” report provides an overview of the disease and market size of Oral Mucositis for the 7MM major pharmaceutical markets, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This report covers the various treatment practices, and Oral Mucositis forecasted epidemiology from 2020 to 2030, segmented by the 7 major markets.

Some of the key facts of the Oral Mucositis Market Report:

Increase in OM market size is anticipated for the study period, 2018–2030 with a CAGR of 6.6%.
As per the research study of Seiler et al. (2014), in the breast cancer patients approximately 56% of the patients developed OM of any grade, 48% patients experience mild to moderate grade 1–2 OM, and 8% grade 3–4 OM according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) scale version 3.0.
In the year 2020, the total incident cases of Oral Mucositis were 1,480,453 cases in the 7MM. These cases are expected to grow in the study period 2018–2030.
As per the DelveInsight estimates, in the United States, the total Grade-specific incident cases of Oral Mucositis were 156,729, 136,107, 209,660, and 94,175 for Grade I, Grade II, Grade III, and Grade IV respectively in the year 2020. These cases are expected to grow in the study period 2018–2030.
As per the research study of Sonis et al., the frequency of oral mucositis is about 30% to 40% in the general cancer patient population.

Request for Sample Pages: https://www.delveinsight.com/sample-request/oral-mucositis-om-market

Key benefits of the Oral Mucositis Market Report:

Oral Mucositis market report covers a descriptive overview and comprehensive insight of the Oral Mucositis epidemiology and Oral Mucositis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
Oral Mucositis market report provides insights on the current and emerging therapies.
Oral Mucositis market report offers a global historical and forecasted market covering drug outreach in 7 MM.
Oral Mucositis market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Malignant Mesothelioma market.

Request for Sample Pages: https://www.delveinsight.com/sample-request/oral-mucositis-om-market

“According to Delveinsight, females appear to be more likely than males to develop Oral mucositis.”

Oral Mucositis (OM) is the most common, debilitating complication of cancer chemotherapy and radiotherapy. It is characterized by inflammation and ulceration in the oral cavity caused by the chemotherapeutic drug substances and radiotherapy used in cancer treatment. The symptoms appear after five to ten days after the chemotherapy treatment or 14 days after the start of radiotherapy. The early symptoms include erythema and light discoloration of the mucosa. As OM progresses, erosive lesions and ulcers are developed.

Mouth sores are extremely painful and are typically the most distressing manifestation. It has significant negative impact on patient’s quality of life (QOL). Potential complications of OM include pain, increased risk of local and systemic infections, bleeding, insufficient food intake, and delays in administration of radiotherapy and/or chemotherapy, dose reduction of the chemotherapy drugs, increased length of hospital stays, associated economic burdens and in some cases life-threatening infections (septicemia in neutropenic cases).

“As per DelveInsight insights, the incidence of Grade I and II OM has been observed to be higher in comparison to Grade III-IV cases across all the major markets”

Request for Sample Pages: https://www.delveinsight.com/sample-request/oral-mucositis-om-market

Some of the Oral Mucositis Companies are:

Amgen/ Swedish Orphan Biovitrum
Access Pharmaceuticals
Chemo Mouthpiece/ Aurora BioScience
Camurus
Innovation Pharmaceuticals
Enzychem Lifesciences Corporation
BrainCool
NeoMedLight
Monopar Therapeutics
MuReva (Lumitex)
EpicentRx/Prothex Pharma
Soligenix
And Many Others.

The launch of the emerging therapies is expected to significantly impact the Oral Mucositis treatment scenario in the upcoming years:-

Oral Mucositis Drugs Covered:

Kepivance (Palifermin)
MuGard
Chemo Mouthpiece
Episil
Brilacidin
EC-18
Cooral System
CareMin650
Validive (Clonidine Lauriad)
MuReva Phototherapy System
RRx-001
SGX942
And Many Others.

Request for Sample Pages: https://www.delveinsight.com/sample-request/oral-mucositis-om-market

Table of Contents:

Key Insights
Executive Summary of Oral Mucositis
SWOT Analysis of Oral Mucositis
Oral Mucositis: Market Share (%) Distribution Overview at a Glance: By Country
Epidemiology and Market Methodology
Oral Mucositis: Disease Background and Overview
Diagnosis of Oral Mucositis
Epidemiology and Patient Population
Epidemiology Scenario: 7MM
The United States Epidemiology
EU-5 Epidemiology
Current Treatment Practices: Oral Mucositis
Prevention of Oral Mucositis
Guidelines of Oral Mucositis
Unmet Needs
Patient Journey of Oral Mucositis
Key Endpoints in Oral Mucositis Clinical Trials
Marketed Therapies
Emerging Therapies
Oral Mucositis: Seven Major Market Analysis
7MM Market Size
The United States Market Size
EU-5 Market Size
Market Access and Reimbursement of Oral Mucositis Therapies
Market Drivers of Oral Mucositis
Market Barriers of Oral Mucositis
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

Related Reports:

· T-Cell-Prolymphocytic Leukemia Market

· Cipn Market

· Barett Esophagus Market

· Post Traumatic Stress Disorder Market

· Oral Mucositis Market

About Delveinsight:

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: [email protected]

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com/

Tags Oral Mucositis (OM), Oral Mucositis (OM) Companies, Oral Mucositis (OM) disease, Oral Mucositis (OM) drugs, Oral Mucositis (OM) epidemiology, Oral Mucositis (OM) market, Oral Mucositis (OM) market forecast, Oral Mucositis (OM) market research, Oral Mucositis (OM) market share, Oral Mucositis (OM) market size, Oral Mucositis (OM) market trends, Oral Mucositis (OM) pipeline, Oral Mucositis (OM) sales forecasting, Oral Mucositis (OM) treatment algorithm

Electric vehicles Energy Environment Finances Military NASA Politics Satellites Science Space Technology

Pipeline Assessment Services | Healthcare Consulting

Post author By sthakur
Post date September 27, 2021
No Comments on Pipeline Assessment Services | Healthcare Consulting

The biopharmaceutical industry is evolving at a fast rate. Biopharmaceutical companies are developing medicines, therapies, inventing new treatment approach to cure various chronic illnesses across dozens of therapeutic areas – including cancer, neurological, diabetes, cardiovascular, rare disease and more.

However, it is a harsh reality that with every 5000 molecules that enter the clinical trials, only one gets approved by the FDA.

In an environment, where healthcare and tax reforms are strict and regulatory decisions are uncertain, biopharmaceutical companies are proactively managing their pipeline products, seizing every opportunity to expand their pipeline portfolio.

Here, R&D becomes an inherent part of growing and sustaining in the industry. Without a strong pipeline, it becomes impossible to oust in this dynamic biopharmaceutical market. Cutting-edge technology such as AI and IoT is transforming everything from manufacturing and logistics to the very core of biopharmaceutical – R&D.

However, Biopharmaceutical Business Consulting companies ease the work of biopharmaceutical companies by helping them manage their pipeline portfolio by accurately benchmarking the products that would qualify and have a better chance to stand in the market.

Biopharmaceutical Business Consulting companies help biopharmaceutical companies to make informed decisions about drug pipeline prioritization, partnerships and mergers, and acquisitions. Biopharmaceutical business consulting companies help in presenting a better and clear picture of the biopharmaceutical market drivers as well as barriers. They help biopharmaceutical companies to choose their pipeline products wisely with their chances of approval and potential development timelines.

Key Pipeline Assessment services provided by Business consulting companies are:

Assessment of clinical pipeline products
Risk management
Competitive benchmarking
Latest biopharmaceutical market trends
Products in the line, their profiles, launch scenario, and patent expiries
R&D spend on the products

For biopharmaceutical companies to outgrow their competitors, and yield maximum return on their investment, it is imperative to analyze their pipeline products and make a well-informed decision as to which drug molecule to be escalated to clinical trials. Prioritizing the pipeline products is an indispensable aspect and as crucial as drug development itself to grow in the biopharmaceutical industry.

Tags Biotech Competitive intelligence, Biotech Consulting, Competitive intelligence, Competitive intelligence service, Consulting, Healthcare Consultancy, Healthcare Consulting, Lifescience Consulting, Pharmaceutical Consulting

Electric vehicles Energy Environment Finances Military NASA Politics Satellites Science Space Technology

Biotech Consulting | Pharmaceutical Consulting | Healthcare Consulting

Post author By sthakur
Post date September 27, 2021
No Comments on Biotech Consulting | Pharmaceutical Consulting | Healthcare Consulting

A consulting company is a company that dedicatedly render consulting, advisory services and un-biased feedback to any organization or any individual. Consulting companies target specific industries and deliver solutions to various sorts of issues faced by different companies. A steep rise in tertiary sector has given rise to a separate new industry in the tertiary sector, consulting services. The last decade saw the emergence of 10 of the largest consulting firms with revenue worth 170 Million dollars and an average annual growth rate of 4%. Not even a single industry is left where consulting firms have not left their mark. From IT to Financial services, from Healthcare to Accounting, subject-matter experts and consultants proffer advisory services to them for effective business decision-making.

Biotech Consulting Firms in Biotechnology

A magnificent hike in the number of pharmaceutical and healthcare companies has exemplified the decisive emergence of the separate industry of biotechnology consulting companies dedicated to its management and regulation. Several regulatory disputes, conflicts and licensing issues have also fueled the demand of Biotech consultants for the better execution of healthcare business.

Biotechnology Consulting Companies (Biotech consulting) are the companies that are involved in assisting healthcare, pharmaceutical and medical devices companies involved in R&D, clinical development, production and commercialization of their products and services. Biotechnology consulting firms emanates strategic approaches to ensure optimization and validation of assay’s selectivity, specificity and quantitation. Biotech consulting companies enable seamless transition of lab data and guidelines of production by assimilating R&D with the process and product development.

The biotech consulting services are tendered in the form of elucidated biotech market reports, advisory services regarding mergers, acquisitions, product launch, and biotech market analysis to keep biotech firms well-informed about the prevailing trends of the market. Some of the best Biotech consulting companies are LEK, Bain, BCG, DelveInsight and many more.

Biotech consulting companies bestowed with experienced and dedicated in-house KOLs, and analysts propose valuable insights on epidemiology, marketed and emerging drugs, competitive drugs, and overall market outlook related to specific indication.

The end-goal of the Biotech consulting firms is to support life science vertical throughout the process and provide efficient and optimized business solutions. Biotech consultants through extensive primary and secondary market research present a detailed overlay of the biotech market, penning down various drivers and barriers driving the biotech market. Biotech consultants streamline the business strategies helping biotech companies to overcome several challenges like drug commercialization, with in-licensing and out-licensing and patents.

The consulting services also include Competitor Benchmarking, Analyzing and Monitoring Clinical Trials, clinical and commercial aspects of R&D, Optimization of Research Strategies etc.

In this fast-paced Biotech environment, it becomes indispensable for the Biotech companies to ally with the right organizations for competent business building. The process of development of a drug is itself a tiresome and lengthy process which takes many years. First the Research phase, then the preclinical phase, clinical phase and then the focus shifts towards the improving efficiency of the results. However, with the emergence of the Biotech consulting companies, there is no need for such laborious tracking of clinical trials and their results, erroneous approaches, possible flaws in the designing of the trials process, and time-intensive and cumbersome preservation of records.

https://okera-consulting.medium.com/

https://okera-consulting.medium.com/healthcare-consulting-9f8aa9269731

https://okera-consulting.medium.com/barretts-esophagus-market-size-is-expected-to-grow-with-sustainable-cagr-5f3e014575a4

Tags Biotech Competitive intelligence, Biotech Consulting, Competitive intelligence, Competitive intelligence service, Consulting, Healthcare Consultancy, Healthcare Consulting, Lifescience Consulting, Pharmaceutical Consulting

Electric vehicles Energy Environment Finances Military NASA Politics Satellites Science Space Technology

How Competitive intelligence is transforming the scenario for Biotech firms?

Post author By sthakur
Post date September 27, 2021
No Comments on How Competitive intelligence is transforming the scenario for Biotech firms?

What is Competitive intelligence service?

Competitive intelligence ideally means gathering information on rival business in the market, analyse the information and use the information to strategize to yield positive results.

Going by the definition, competitive intelligence assembles actionable information from diverse published and unpublished sources, collected efficiently and ethically.

So, analysts performing Competitive intelligence for their clienteles present a detailed picture of the marketplace, forthcoming challenges and the ways to face them, even before the can harm the client’s business.

What could it mean?

Competitive intelligence can often give a wrong idea, as it may misunderstood as a service which can help gain an advantage over the rivals.

However, this is not the case. Competitive intelligence is an ethical and legal practise undertaken involving the study of analytical data, analysing the market and optimizing the relevant and realistic strategies to protect the client from fluctuations in the market.

Biotech Competitive intelligence

Biotech Competitive intelligence is crucial as it helps to develop a support system. The Biotech consulting firms perform the efficient approaches to enter into market, extensive R&D on competitors, and provide professional advices to stay in the market for long run.

Biotech consultants and analysts provide comprehensive knowledge and opinions in technological

Biotech Competitive intelligence: A long process

The first step of the process is dedicated primary research to recognise the unmet needs in the field of the indication in question. Biotech consulting involves the study of the present therapies for the indication, if the standard care is available to the patient pool and if yes, then what is the propensity of the side effects.

The well-informed study of pre-discovery phase is an important step of the Biotech consulting.

After, Primary research, Biotech consultants undertake in-depth elucidated research to find out the new technological advancements that can help Biotech and pharma companies to advance their respective pipeline.

Throughout the whole process, Biotech consulting firms keep themselves as well as the clients well-informed. This helps to strengthen the foundation of the Biotech firms in the Healthcare domain.

Tags Biotech Competitive intelligence, Biotech Consulting, Competitive intelligence, Competitive intelligence service, Consulting, Healthcare Consultancy, Healthcare Consulting, Lifescience Consulting, Pharmaceutical Consulting

Electric vehicles Energy Environment Finances Military NASA Politics Satellites Science Space Technology Uncategorized

Asset Management Consulting Services | Healthcare Consulting

Post author By sthakur
Post date September 27, 2021
No Comments on Asset Management Consulting Services | Healthcare Consulting

In today’s dynamic world, relying on one asset can be a reason of downfall of any company- be it of any scale- in case of recession, or any kind of crisis. Having multiple assets allows diversified portfolio, numerous ways to invest, thus reduces risk.

But how do you manage your assets? Here comes the role of Asset prioritization services.

In the Pharmaceutical industry, the same way, it is imperative for pharmaceuticals to manage their assets as per the scenario in the pharma market. Asset prioritization services help pharma companies in gauging the multiple variants that steer the pharma market, helping them strategizing the best possible decision for their assets. The moves like selling off assets, initiating any further study of the asset, licensing of any asset, or just to take time and analyze the market, all of it is extensively undertaken and comprehensively presented by Asset management consulting services.

DelveInsight, a leading Pharma and Healthcare Business Research and Consulting firm, is devoted to helping pharma companies in pharma asset prioritization. The company proffers consulting services in the pharma and healthcare sector for better management of assets in their vast portfolio. As per DelveInsight’s analysts, with Pharma asset prioritization, it becomes easier to manage risk. The pharma companies invest a lot of time and money in developing novel molecules, and compounds for treating a disease. The pre-clinical phase, human-trials, getting approval from different regulatory authorities, and then commercialization of the product alone, takes maximum years of the patent period. Then, there comes the competition from several other companies, and the entry of generics after patent expiration. The process is cumbersome and time-consuming. DelveInsight’s Asset prioritization services help in measuring the pros and cons of each business decision, hence advise the companies to put their particular asset up on the pedestal focusing on either license-in, license out, selling, buying, or giving exclusive focus to a specific asset based on the present pharma market trends, and calculated forecast. Not only this, the companies who have their products still in the pre-clinical phase, DelveInsight’ Pharma asset prioritization services help them with by analyzing the future scope of their innovation, guiding them through the process.

There are several factors to be considered while managing assets under pharma asset prioritization, such as:

Stage of development of the molecule
The geography and the regulatory guidelines
Competitive molecules
Need and situation of the client
Present pharma market trends and NPV (Net present value) of the molecule
Innovation behind the molecule development
Indication to be targeted, and epidemiological analysis, and several others

Overall, valuation of the assets is an indispensable aspect of the business growth for not only pharma companies but every industry striving to survive and excel in their respective field.

Tags Asset Management Consulting Services, Biotech Consulting, Consulting, Healthcare Consultancy, Healthcare Consulting, Lifescience Consulting, Pharmaceutical Consulting

Electric vehicles Energy Environment Finances Military NASA Politics Satellites Science Space Technology

Atherosclerosis Pipeline, Clinical Trial, Treatment, Therapies And Key Pharma Players Involved By DelveInsight | Regeneron, Sanofi, Immunitor, Novartis, MedImmune, Cerenis Therapeutics, AFFiRiS, VBL Therapeutics, Abcentra And Others

Atherosclerosis is a slow, lifelong progression of changes in the blood vessels that may start in childhood and get worse faster with the age. Atherosclerosis usually doesn’t cause any symptoms until blood supply to an organ is reduced. When this happens, symptoms vary, depending on the specific organ involved: Heart — Symptoms include the chest pain of angina and shortness of breath, sweating, nausea, dizziness or light-headedness, breathlessness or palpitations. Brain — When atherosclerosis narrows brain arteries, it can cause dizziness or confusion; weakness or paralysis on one side of the body. Abdomen — When atherosclerosis narrows the arteries to the intestines, there may be dull or cramping pain in the middle of the abdomen. There is no cure for atherosclerosis, but treatment can slow or halt the worsening of the disease. The major treatment goal is to prevent significant narrowing of the arteries so that symptoms never develop and vital organs are never damaged.

DelveInsight’s, “Atherosclerosis Pipeline Insight, 2021” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Atherosclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Some of Atherosclerosis Companies are:

Regeneron/Sanofi
Immunitor
Novartis
MedImmune
Cerenis Therapeutics
AFFiRiS
VBL Therapeutics
Abcentra
Millennium Pharmaceuticals
Daiichi Sankyo
Band Therapeutic
Innomedica
Chugai Pharmaceutical
Repair Biotechnologies
Northstar medical radioisotopes
Entos therapeutics
Caladrius Biosciences
Novo Nordisk
Esperion Therapeutics
Immusoft Corp
Kaleido Biosciences
Takeda Pharmaceutical
MetrioPharm
And Many Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight

DelveInsight’s Atherosclerosis report covers around 25+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Some of Atherosclerosis Therapies are:

Alirocumab
Tofogliflozin
VB 201
atherosclerosis vaccine
ATH 04
BT 200
actinium-225/bismuth-213
Inclisiran
CLBS12
CER-001
Plozalizumab
Canakinumab
DS 8190
MEDI6012
Orticumab
Forskolin/rolipram liposomal
And Many Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight

Current Atherosclerosis Treatment Scenario and Atherosclerosis Emerging Therapies:

How many companies are developing Atherosclerosis drugs?
How many Atherosclerosis drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atherosclerosis?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Atherosclerosis therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Atherosclerosis and their status?
What are the key designations that have been granted to the emerging drugs?

Request for Free Sample Report: https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight

Table of Contents:

Introduction

Executive Summary

Atherosclerosis: Overview

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Atherosclerosis – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

Atherosclerosis Collaboration Deals

Late Stage Products (Regsitered)

Comparative Analysis

Aloricumab: Sanofi/ Regeneron

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

Comparative Analysis

VB 201: VBL therapeutics

Drug profiles in the detailed report…..

Early stage products (Phase I)

Comparative Analysis

BT 200: Band Therapeutics

Drug profiles in the detailed report…..

Inactive Products

Comparative Analysis

Atherosclerosis Key Companies

Atherosclerosis Key Products

Atherosclerosis- Unmet Needs

Atherosclerosis- Market Drivers and Barriers

Atherosclerosis- Future Perspectives and Conclusion

Atherosclerosis Analyst Views

Atherosclerosis Key Companies

Appendix

Request for Detailed TOC: https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight

Get in touch with our Business executive for Business Consulting Solutions

Related Reports:

Intrahepatic Cholangiocarcinoma Market
Barett Esophagus Market
Aortic Stenosis Market
Chemotherapy Induced Diarrhea Market
Immunologic Deficiency Syndrome Market
Acquired Immunodeficiency Syndrome (AIDS) Market
Bladder pain syndrome Market
Cardiac Arrythmia Market
Cardiorenal Syndrome Market
Carpal Tunnel Syndrome Market
Central Retinal Venous Occulsion Market
Foot and Ankle Devices Market

DelveInsght’s Licensing service includes a multidimensional coverage, helping to keep track of competitors and gain traction in the dynamic market by overcoming the challenges and expediting business growth through a strategic and tactical approach.

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: [email protected]
Phone: +19193216187
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Tags Atherosclerosis, Atherosclerosis clinical trials, Atherosclerosis companies, Atherosclerosis Pipeline